Boston Scientific earnings release, July 29, 2026
Boston Scientific announces results for second quarter 2026
Marlborough, Mass. (July 29, 2026) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational¹ and organic² basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted³
EPS of $0.86 for the period, compared to $0.75 a year ago.
"Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."
Second quarter financial results and recent developments:
• Reported net sales of $5.442 billion, representing an increase of 7.5 percent on a reported basis, compared to the company's guidance range of 5.5 to 7.5 percent; and 7.0 percent on an operational and organic basis, compared to the company's guidance range of 5 to 7 percent, all compared to the prior year period.
• Reported GAAP net income attributable to Boston Scientific common stockholders of $0.61 per share, and achieved adjusted EPS of $0.86 per share, compared to the guidance range of $0.82 to $0.84 per share.
• Achieved the following net sales growth in each reportable segment, compared to the prior year period:
◦ MedSurg: 5.9 percent reported, 5.4 percent operational and organic
◦ Cardiovascular: 8.3 percent reported, 7.8 percent operational and organic
• Achieved the following net sales growth in each region, compared to the prior year period:
◦ United States (U.S.): 6.2 percent reported and operational
◦ Europe, Middle East and Africa (EMEA): 6.1 percent reported and 4.2 percent operational
◦ Asia-Pacific (APAC): 11.2 percent reported and operational
◦ Latin America and Canada (LACA): 22.4 percent reported and 16.2 percent operational
• Completed the previously announced $2 billion accelerated share repurchase program, repurchasing approximately 40 million shares.
• Invested $1.5 billion in
MiRus LLC, which is developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases, including the
SIEGEL™ Balloon Expandable Transcatheter Aortic Valve Replacement (TAVR) system, in return for an approximately 34% equity stake and exclusive option to acquire the MiRus TAVR business.⁴
• Presented late-breaking findings at EuroPCR from the FRACTURE Investigational Device Exemption trial, which met its primary endpoints with the
SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter, demonstrating high rates of freedom from major adverse cardiac events at 30 days as well as procedural success in patients with severely calcified coronary artery disease.⁴
• Announced clinical trial results that were presented in late-breaking sessions at Heart Rhythm 2026 including:
◦ The AVANT GUARD study of
FARAPULSE™ Pulsed Field Ablation (PFA) for the treatment of persistent atrial fibrillation (AF) in patients who had not previously been treated for their condition. Data met all safety and effectiveness endpoints and demonstrated statistical superiority of FARAPULSE PFA over anti-arrhythmic drugs with significantly higher primary effectiveness.
◦ The ELEVATE-PF feasibility study of the
FARAFLEX™ Mapping and PFA Catheter — a novel large focal, high-density map-and-ablate catheter — in patients with paroxysmal and persistent AF. The trial demonstrated strong lesion durability validated by cardiac remapping, with no reported cases of pulmonary vein stenosis, hemolysis, coronary spasm or clinical stroke.⁴
• Commenced enrollment in the pivotal FARADIGM clinical trial to evaluate the safety and effectiveness of the
FARAFLEX Mapping and PFA Catheter for treating patients with paroxysmal and persistent AF.⁴
• Received U.S. Food and Drug Administration 510(k) clearance for the
TruSelect™ 2.6 Microcatheter, expanding Boston Scientific's embolization portfolio with a device designed to provide physicians with a single solution for navigation and efficient embolic delivery during minimally invasive procedures.
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited) (in millions, except per share data)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Net sales | 5,442 | 5,061 | 10,646 | 9,724 | |
| Cost of products sold (excluding amortization expense) | 1,594 | 1,637 | 3,184 | 3,090 | |
| Gross profit | 3,848 | 3,424 | 7,462 | 6,633 | |
| Operating expenses: | Selling, general and administrative expenses | 1,803 | 1,716 | 3,583 | 3,312 |
| Operating expenses: | Research and development expenses | 554 | 526 | 1,069 | 969 |
| Operating expenses: | Royalty expense | 12 | 14 | 24 | 28 |
| Operating expenses: | Amortization expense | 233 | 225 | 466 | 444 |
| Operating expenses: | Intangible asset impairment charges | 46 | 46 | ||
| Operating expenses: | Contingent consideration net expense (benefit) | -16 | -5 | -46 | 0 |
| Operating expenses: | Restructuring net charges (credits) | 8 | 83 | 11 | 93 |
| Operating expenses: | Litigation-related net charges (credits) | 76 | 76 | ||
| Operating expenses: | 2,670 | 2,605 | 5,183 | 4,894 | |
| Operating expenses: | Operating income (loss) | 1,178 | 819 | 2,279 | 1,740 |
| Other income (expense): | Interest expense | -96 | -90 | -186 | -172 |
| Other income (expense): | Other, net | -23 | 213 | 129 | 179 |
| Other income (expense): | Income (loss) before income taxes | 1,060 | 941 | 2,222 | 1,746 |
| Other income (expense): | Income tax expense (benefit) | 155 | 146 | -21 | 279 |
| Other income (expense): | Net income (loss) | 905 | 795 | 2,243 | 1,467 |
| Other income (expense): | Net income (loss) attributable to noncontrolling interests | -2 | -2 | -4 | -4 |
| Other income (expense): | Net income (loss) attributable to Boston Scientific common stockholders | 907 | 797 | 2,247 | 1,471 |
| Other income (expense): | Net income (loss) per common share - basic | 0.62 | 0.54 | 1.52 | 0.99 |
| Other income (expense): | Net income (loss) per common share - diluted | 0.61 | 0.53 | 1.51 | 0.98 |
| Weighted-average shares outstanding | Basic | 1,470.2 | 1,479.9 | 1,477.6 | 1,478.5 |
| Weighted-average shares outstanding | Diluted | 1,474.8 | 1,493.5 | 1,484.9 | 1,493.3 |
Full release
1. Operational net sales growth excludes the impact of foreign currency fluctuations.
2. Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales.
3. Adjusted EPS excludes the impact of certain charges (credits) as defined below within the "Use of Non-GAAP Financial Measures" section.
4. The SIEGEL Balloon Expandable TAVR system, the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter and the FARAFLEX Mapping and PFA Catheter are investigational devices. Limited by Federal (or U.S.) law to investigational use only. Not available for sale.
Net sales for the second quarter by business and region:
Guidance for Full Year and Third Quarter 2026
The company now estimates net sales growth for the full year 2026, versus the prior year period, to be approximately 5.5 to
6.5 percent on a reported basis and 5 to 6 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company now estimates adjusted EPS, excluding certain charges (credits), of $3.28 to $3.32.... (truncated)e third quarter of 2026, versus the prior year period, to be approximately 3 to 5 percent on a reported and organic basis. Third quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates adjusted EPS, excluding certain charges (credits), of $0.80 to $0.82.
The company has not provided reconciliations of the forward-looking adjusted EPS guidance to GAAP guidance as it is unable to predict with reasonable certainty and without unreasonable efforts the impact of certain items such as intangible asset impairment charges, acquisition-related charges, restructuring and restructuring-related charges and litigation-related charges. The combined impact of these items is uncertain, dependent on various factors and cannot be predicted with reasonable certainty, and could be material to our GAAP measures of financial results.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on
LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; adjusted EPS for the third quarter and full year 2026; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
Note... (truncated)rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.